Announcement PDF RNS Number : 5834S OptiBiotix Health PLC 17 November 2021 OptiBiotix Health plc ("OptiBiotix" or the "Company" or the "Group") Formation of OptiBiotix Health India OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds that modulate the microbiome to tackle metabolic syndrome, systemic low grade inflammation, obesity and diabetes, cardiovascular disease and high cholesterol, announces the formation of its new Indian subsidiary, OptiBiotix Health India Ltd ("OHI"). With a population of 1.3 billion people and cardiovascular disease accounting for up to 27% of all deaths (WHO) and obesity prevalence at 40.3% (https://journals.sagepub.com/doi/full/10.1177/0972753120987465), India is a market of great strategic importance to OptiBiotix. The formation of OHI allows significant opportunities for additional revenue growth through sales of the Group's products in India. The middle-class population in India is expected to reach 475 million by 2030. Currently most middle-class consumers live in the European Union (EU) and the United States, but over the next decade, the majority will shift heavily toward India, with one in four global middle-class consumers expected to reside in India by 2035 https://www.asianstudies.org/publications/eaa/archives/the-middle-class-in-india-from1947-to-the-present-and-beyond/. The nutraceuticals market in India is expected to grow from $4 billion in 2017 to $18 billion in 2025 against the backdrop of rising demand for dietary supplements from upper and middle class https://www.investindia.gov.in/team-india-blogs/growingnutraceuticals-market-india. In March 2021, OptiBiotix announced the appointment of Dr Taru Jain to focus on business development and growing sales in the strategically important Indian and Asian markets. The formation of OHI builds on that presence and is expected to bring the following benefits:· OHI will be able to manage the purchase and sale of ingredients (e.g. LPLDL®, SlimBiome®) and final product (e.g. CholBiome® range, GoFigure®) manufactured and sold in India increasing operational efficiency and partner engagement. This is highly challenging without a physical presence in India · OHI will buy ingredients from its ingredients manufacturers, sell to product manufacturers, and then buy and sell final product through partners, deriving value from all parts of the supply chain · We anticipate this will result in greater sales at improved margins and if successful make a significant contribution to revenue growth. The ability to sell both ingredient and final product leads to a double impact on revenues and will allow OptiBiotix to protect its brands from the risk of commoditisation · OHI will be able to benefit from reduced or negligible import, export, and General Sales Taxes which would be charged in the absence of a local company presence. The formation of OHI allows OptiBiotix to migrate existing profit-sharing agreements (RNS:7 January 2019, 16 May 2018) to manufacture and supply agreements. This allows the Company to manage and extract value from all areas of the supply chain to better exploit the market opportunity India represents. Stephen OHara, CEO of OptiBiotix Health plc, commented: "We are pleased to announce the setting up of a subsidiary in India, a country we have identified as of strategic importance for its high growth potential and access to Asian markets. This is all part of our plans to grow sales, margins, and product ranges with new and existing partners in key strategic markets. Establishing a physical presence allows us to maximise the potential opportunity in this market and and if successful make a significant contribution to future sales growth." The Directors of the Company are responsible for the release of this announcement. For further information, please contact: OptiBiotix Health plc Stephen O'Hara, Chief Executive www.optibiotix.com Contact via Walbrook below Cairn Financial Advisers LLP (NOMAD) Liam Murray / Jo Turner / Ludovico Lazzaretti Tel: 020 7213 0880 Cenkos Securities plc (Broker) Callum Davidson / Neil McDonald Michael Johnson / Russell Kerr (Sales) Tel: 020 7397 8900 Walbrook PR Ltd Anna Dunphy Mob: 07876 741 001 Caution regarding forward looking statements Certain statements in this announcement, are, or may be deemed to be, forward looking statements. Forward looking statements are identified by their use of terms and phrases such as ''believe'', ''could'', "should" ''envisage'', ''estimate'', ''intend'', ''may'', ''plan'', ''potentially'', "expect", ''will'' or the negative of those, variations or comparable expressions, including references to assumptions. These forward looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding the Company's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements reflect the Directors' current beliefs and assumptions and are based on information currently available to the Directors. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END MSCFFLFMMEFSEFF